Consequently, enhancing cellular GAS5 lncRNA levels in tumour tissue may not only suppress the growth of such tumours but also enhance tumour cell killing by therapeutic agents, thereby improving patient outcomes. This evidence concerns the gene GAS5 and neoplasm.